FIGURE and TABLE LEGENDS
Figure 1: CONSORT diagram: Patient treatment and outcomes. Pathway followed by all patients enrolled on the Children’s Oncology Group (COG) AALL02P2.
Figure 2: Event free survival (EFS) and overall survival (OS) of COG AALL02P2, and comparison to historical outcomes
2A: Event free survival (EFS) and overall survival (OS) of isolated late CNS-R patients with B-ALL enrolled and treated on COG AALL02P2.
2B: EFS COG AALL02P2 compared to historical outcomes of similar patients treated on POG 9412.
2C: OS COG AALL02P2 compared to historical outcomes of similar patients treated on POG 9412.
Figure 3: Event free survival (EFS) and overall survival (OS) of isolated CNS-R patients with B-ALL on COG AALL02P2, stratified by NCI risk group and compared to historical outcomes of similar patients on POG 9412.
3A: EFS NCI HR patients, comparison between COG AALL02P2 and POG 9412.
3B: OS NCI HR patients, comparison between COG AALL02P2 and POG 9412.
3C: EFS NCI SR patients, comparison between COG AALL02P2 and POG 9412.
3D: OS NCI SR patients, comparison between COG AALL02P2 and POG 9412.
Figure 4: Minimal residual disease (MRD) status and outcomes
4A: EFS by MRD status (0.01% cutoff)
4B: OS by MRD status (0.01% cutoff)
4C: EFS by MRD status (0.1% cutoff)
4D: OS by MRD status (0.1% cutoff)
Table 1 Summary of relapses by NCI risk group and relapse site
Supplemental Figure 1: Cumulative incidence of relapse by NCI risk group
Supplemental Table 1: COG AALL02P2 protocol design
Supplemental Table 2: Summary of event free survival (EFS) events